CelLBxHealth (LSE:CLBX) has reaffirmed its commercial outlook at its annual general meeting, highlighting continued demand for its live circulating tumour cell (CTC) capture technology and announcing the start of a search for a new chief executive.
The company said its Parsortix platform continues to address an important clinical need in areas where circulating tumour DNA (ctDNA) testing is less effective. Management noted that the technology is attracting growing interest from pharmaceutical companies and clinicians, with its ability to integrate into existing laboratory workflows providing deeper oncology insights and supporting multiple revenue opportunities.
The board reiterated its expectation of generating at least £2.1 million in revenue during the 2026 financial year, representing projected growth of approximately 50% compared with FY2025. Management said the core business strategy and commercial outlook remain unchanged despite the planned leadership transition.
Executive Chairman Jan Groen will continue in his role while the company conducts its search for a new chief executive. The board said it has sufficient senior leadership in place to ensure business operations and commercial activities continue without disruption throughout the recruitment process.
Although CelLBxHealth remains focused on expanding the commercial adoption of its technology, its outlook continues to reflect the challenges facing an early-stage healthcare company. Financial performance and valuation remain under pressure, while technical indicators suggest continued weakness in the share price. However, management believes recent operational progress and commercial milestones provide a solid foundation for future growth.
About CelLBxHealth plc
CelLBxHealth plc is an oncology diagnostics company specialising in circulating tumour cell (CTC) technologies for research, drug development and clinical applications. Its patented Parsortix platform captures live circulating tumour cells from blood samples and integrates with existing laboratory systems to support advanced imaging, proteomic profiling and genomic analysis.
The company’s business model combines sales of the Parsortix platform and consumables with laboratory services for clinical trials, assay development through its GCLP-compliant UK facility, and the development of laboratory-developed tests through strategic partnerships and internal research programmes.
Leave a Reply